# A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer

> **NCT01017874** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 236 (actual)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Pemetrexed
- **DRUG:** Cisplatin
- **DRUG:** Gefitinib
- **DRUG:** Gefitinib

## Key facts

- **NCT ID:** NCT01017874
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2013-04
- **Final completion:** 2014-10
- **Target enrollment:** 236 (ACTUAL)
- **Last updated:** 2015-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01017874

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01017874, "A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01017874. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*